Teicoplanin

Generic Name: Teicoplanin

Drug Type: Small Molecule

Chemical Formula: C_₈₈H_₉₇Cl_₂N_₉O_₃₃

CAS Number: 61036-62-2

Unique Ingredient Identifier: 4U3D3YY81M

Background: Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.

Indication: For the treatment of bacterial infections caused by susceptible microorganisms.

Associated Conditions: Angina Pectoris, Anginal Pain, Bacteremia, Bloodstream Infections (BSI), Bone and Joint Infections, Clostridium Difficile, Clostridium Difficile Infection (CDI), Community Acquired Pneumonia (CAP), Complicated Urinary Tract Infection, Infective Endocarditis (IE), Lower Respiratory Tract and Lung Infections, Non-complicated Skin and Soft Tissue Infections, Nosocomial Pneumonia, Peritonitis, Skin and Soft Tissue Infections (SSTIs), Urinary Tract Infection

Clinical Trials

Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.

Not Applicable

Not yet recruiting

Conditions: Acute-On-Chronic Liver Failure

Interventions: Drug: Meropenem Injection
Drug: Ceftazidime-avibactam
Drug: Teicoplanin

First Posted Date: 2025-02-10

Last Posted Date: 2025-02-10

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 150

Registration Number: NCT06818565

Locations: 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

TDM-optimized Teicoplanin Dosing Versus Standard of Care

Phase 4

Recruiting

Conditions: Bacterial Infections

Interventions: Drug: Teicoplanin

First Posted Date: 2023-06-22

Last Posted Date: 2024-04-16

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 74

Registration Number: NCT05914467

Locations: 🇳🇱
RadboudUMC, Nijmegen, Netherlands

Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy

Phase 4

Completed

Conditions: Cholangitis, Secondary Biliary
Treatment Compliance
Antibodies Drug Specific

Interventions: Drug: Sulperazon
Drug: Meropenem Injection
Drug: Teicoplanin

First Posted Date: 2020-04-30

Last Posted Date: 2022-04-11

Lead Sponsor: Tongji Hospital

Target Recruit Count: 160

Registration Number: NCT04370145

Locations: 🇨🇳
Tongji hospital affiliated to tongji medical college of huazhong university of science and technology, Wuhan, Hubei, China
🇨🇳
TongjiHospital, Wuhan, Hubei, China

Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection

Phase 3

Conditions: Scoliosis Lumbar Region
Lumbar Disc Lesion
Lumbar Spondylolisthesis
Lumbar Spinal Stenosis
Lumbar Disc Herniation

Interventions: Drug: Teicoplanin

First Posted Date: 2020-04-10

Last Posted Date: 2020-04-14

Lead Sponsor: Bezmialem Vakif University

Target Recruit Count: 120

Registration Number: NCT04341831

Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.

First Posted Date: 2019-11-25

Last Posted Date: 2020-12-09

Lead Sponsor: Neupharma Srl

Target Recruit Count: 12

Registration Number: NCT04176328

Locations: 🇮🇹
Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

Efficacy and Safety of Teicoplanin in CDAD

Phase 4

Terminated

Conditions: Clostridium Difficile Infection-associated Diarrhea and Colitis

Interventions: Drug: TEICOPLANIN

First Posted Date: 2019-07-01

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 50

Registration Number: NCT04003818

Locations: 🇨🇳
investigational site CHINA, China, China

the Clinical Trial of Teicoplanin for Injection

Conditions: Infectious Disease

First Posted Date: 2017-01-13

Last Posted Date: 2017-01-13

Lead Sponsor: Jiangsu Famous Medical Technology Co., Ltd.

Target Recruit Count: 100000

Registration Number: NCT03020901

PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4

Not Applicable

Recruiting

Conditions: Chronic Skin Ulcer

Interventions: Drug: PRF mixed with PHMB plus Macrogolol
Drug: PRF plus normal saline
Other: Silver gauze
Drug: PRF mixed with amikacin and teicoplanin